REBLOZYL® (luspatercept-aamt) is a prescription medicine used to treat anemia (low red blood cells) in adults with beta thalassemia who need regular red blood cell (RBC) transfusions.
REBLOZYL is not for use as a substitute for RBC transfusions in people who need immediate treatment for anemia.
It is not known if REBLOZYL is safe or effective in children.
This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Starting a new medicine is not something to be taken lightly. You may feel uncertain at first. Knowing how REBLOZYL has impacted other people can help you understand why your doctor prescribed it.
The main goal of the study was to see if REBLOZYL could lower the number of transfusions needed by at least one-third during a set 12-week period compared to placebo.*
People in both treatment groups were allowed to receive best supportive care. This included red blood cell (RBC) transfusions, as needed.
*Set 12-week period was weeks 13–24.
21.4%of people receiving REBLOZYL (48 out of 224 patients)
REDUCED THE NEED
by at least a third over 12 weeks vs 4.5% of people receiving placebo (5 out of 112 patients)
which means that
greater percentage of patients receiving REBLOZYL reduced their transfusion burden vs placebo
Example patient: What this might look like
For example, if a patient needed 6 RBC units every 12 weeks before starting REBLOZYL…
…this patient may only need 4 (or less) RBC units during weeks 13 to 24 after starting REBLOZYL
Patients could not be a part of the study if they were under 18 or had:
It’s important to know about the possible side effects of REBLOZYL before beginning treatment. Remember: people may react to medicines differently, and that’s expected.
The possible side effects of REBLOZYL are well-known. Be sure to talk with your healthcare team about what to expect when starting treatment with REBLOZYL.